Print this page

ITL announces today a major initiative to become a leader in the field of immunomonitoring technology and analysis

Immunomonitoring is the study of the intersection of the immune system and the tumor. The immune system is known to be capable of recognizing and eliminating tumors and remembering the tumor for fast elimination in the event of recurrence. However, in cancer the tumor evades immune destruction and grows unaffected by immune killing mechanisms.

In the past, cancer clinical trials evaluated the effectiveness of drugs upon their ability to cause tumors to shrink. There is often a correlation between shrinkage of tumor and extension of survival. As waiting for clinical survival data to mature can be long and expensive, tumor shrinkage became an acceptable surrogate marker of response that enabled response data to be determined in much shorter time. This benefit is not available to immunotherapy drug clinical development, as immunotherapy often causes tumors to increase in size due to swelling or a late responses give impression initially as a non-response.

ITL has now developed a sophisticated suite of immunological tests to analyze patient blood and tissue samples. These tests are expected to enable us to understand the immune responses in patients on an individual basis and eventually develop new short cut markers to predict response.

Watch for news as these new tests are brought online.